Second, GDF15 binds to its receptor GFRAL and activates a chronic inflammatory response via the PI3K/AKT/STAT3 pathway, which induces an imbalance in oxidative stress, resulting in increased tumor burden and drug resistance. Here, STAT3 is linked to neoplasm.